Targeted drug delivery to the nucleus and its potential role in cancer chemotherapy

Journal of Pharmaceutical Sciences and Research

Volumn 5, Issue 2, 2013, Pages 48-56

  Deepthi, A ^a   Raju, S ^c   Kalyani, A ^a   Udaya Kiran, M ^b   Vanaja, A ^a  

^a StPauls College Of Pharmacy   (India)

^b Department of Pharmaceutics   (India)

^c Shantha Biotechnics Limited   (India)

Author keywords

Biological barriers; Chemotherapy; Nuclear targeted drug delivery; Tumour cells

Indexed keywords

10 HYDROXYCAMPTOTHECIN; CISPLATIN; CURCUMIN; DOXORUBICIN; ELACRIDAR; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; FOLATE RECEPTOR; GONADORELIN RECEPTOR; INTEGRIN; KARYOPHERIN ALPHA; KARYOPHERIN BETA; MULTIDRUG RESISTANCE PROTEIN; NANOCARRIER; NANOPARTICLE; PROSTATE SPECIFIC MEMBRANE ANTIGEN; SMALL INTERFERING RNA; TARIQUIDAR; TOCOFERSOLAN; TRANSFERRIN;

ADENOVIRUS; ARTICLE; CANCER CHEMOTHERAPY; CELL KILLING; CYTOPLASM; CYTOTOXICITY; DRUG DELIVERY SYSTEM; LYSOSOME; NUCLEAR LOCALIZATION SIGNAL; NUCLEAR TARGETED DRUG DELIVERY; NUCLEOCYTOPLASMIC TRANSPORT; PERMEABILITY BARRIER; PH; PHOTODYNAMIC THERAPY;

EID: 84874676430     PISSN: 09751459     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (76)

1. Sobolev, A.S., Jans, D.A., Rosenkranz, A.A., Targeted intracellular delivery of photosensitizers. Prog. Biophys. Mol. Biol. 2000, 73, 51-90.
2. Rosenkranz, A.A., Lunin, V.G., Gulak, P.V., Sergienko, O.V., Shumiantseva, M.A., Voronina, O.L., Gilyazova, D.G., John, A.P., Kofner, A.A., Mironov, A.F., Jans, D.A., Sobolev, A.S., Recombinant modular transporters for cell-specific nuclear delivery of locally acting drugs enhance photosensitizer activity. FASEB J. 2003, 17, 1121-1123.
3. L. Rajendran, H.J. Knolker, K. Simons, Subcellular targeting strategies for drug design and delivery, Nat. Rev. Drug Discov. 2010, 9 (1), 29-42.
4. S.M. Burrow, D.A. Phoenix, M. Wainwright, M.J. Tobin, Intracellular localization studies of doxorubicin and Victoria Blue BO in EMT6-S and EMT6-R cells using confocal microscopy, Cytotechnology. 2002, 39 (1), 15-25.
5. M. Duvvuri, J.P. Krise, Intracellular drug sequestration events associated with the emergence of multidrug resistance: a mechanistic review, Front. Biosci. 2005, 10, 1499-1509.
6. G.D. Wang, E. Reed, Q.Q. Li, Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancer (Review), Oncol. Rep. 2004, 12 (5), 955-965.
7. M.A. Fuertes, C. Alonso, J.M. Perez, Biochemical modulation of cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance, Chem. Rev. 2003,103 (3), 645-662.
8. Alvisi, G., Poon, I.K., Jans, D.A., Tumor-specific nuclear targeting: promises for anti-cancer therapy? Drug Resist. Updat. 2006, 9, 40-50.
9. Wagstaff, K.M., Jans, D.A., Nucleocytoplasmic transport of DNA: enhancing nonviral gene transfer. Biochem. J. 2007, 406, 185-202.
10. Robbins, P.D., Ghivizzani, S.C., Viral vectors for gene therapy. Pharmacol. Ther. 1998, 80, 35-47
11. Glover, D.J., Lipps, H.J., Jans, D.A., Towards safe, non-viral therapeutic gene expression in humans. Nat. Rev. Genet. 2005, 6, 299-310.
12. Wagstaff, K.M., Jans, D.A., Protein transduction: cell penetrating peptides and their therapeutic applications. Curr. Med. Chem. 2006b, 13, 1371-1387.
13. Seth, P., Mechanism of adenovirus-mediated endosome lysis: role of the intact adenovirus capsid structure. Biochem. Biophys. Res. Commun. 1994, 205, 1318-1324.
14. Conner, S.D., Schmid, S.L., Regulated portals of entry into the cell. Nature. 2003, 422, 37-44.
15. Vaughan, E.E., DeGiulio, J.V., Dean, D.A., Intracellular trafficking of plasmids for gene therapy: mechanisms of cytoplasmicmovement and nuclear import. Curr. Gene Ther. 2006, 6, 671-681.
16. Harel, A., Forbes, D.J., Importin beta: conducting a much larger cellular symphony. Mol. Cell. 2004, 16, 319-330.
17. Wente, S.R., Gatekeepers of the nucleus. Science. 2000, 288, 1374-1377.
18. Ribbeck, K., Gorlich, D., Kinetic analysis of translocation through nuclear pore complexes. EMBO J. 2001, 20, 1320-1330.
19. Poon, I.K., Jans, D.A., Regulation of nuclear transport: central role in development and transformation? Traffic.2005, 6, 173-186.
20. Jans, D.A., Chan, C.K., Huebner, S., Signals mediating nuclear targeting and their regulation: application in drug delivery. Med. Res. Rev. 1998, 18, 189-223.
21. Kalderon, D., Richardson, W.D., Markham, A.F., Smith, A.E., Sequence requirements for nuclear location of simian virus 40 large-T antigen. Nature. 1984a, 311, 33-38.
22. Kalderon, D., Roberts, B.L., Richardson, W.D., Smith, A.E., A short amino acid sequence able to specify nuclear location. Cell. 1984b, 39, 499-509.
23. Robbins, J., Dilworth, S.M., Laskey, R.A., Dingwall, C., Two interdependent basic domains in nucleoplasmin nuclear targeting sequence: identification of a class of bipartite nuclear targeting sequence. Cell. 1991, 64, 615-623.
24. Pollard, V.W., Michael, W.M., Nakielny, S., Siomi, M.C., Wang, F., Dreyfuss, G., A novel receptor-mediated nuclear protein import pathway. Cell. 1996, 86, 985-994.
25. Goldfarb, D.S., Corbett, A.H., Mason, D.A., Harreman, M.T., Adam, S.A., Importin alpha: a multipurpose nuclear-transport receptor. Trends Cell Biol. 2004, 14, 505-514.
26. Bayliss, R., Corbett, A.H., Stewart, M., The molecular mechanism of transport of macromolecules through nuclear pore complexes. Traffic. 2000a, 1, 448-456.
27. Bayliss, R., Littlewood, T., Stewart, M., Structural basis for the interaction between FxFG nucleoporin repeats and importin-beta in nuclear trafficking. Cell. 2000b, 102, 99-108.
28. Azuma, Y., Dasso, M., The role of Ran in nuclear function. Curr. Opin. Cell Biol. 2000, 12, 302-307.
29. Hogarth, C.A., Calanni, S., Jans, D.A., Loveland, K.L., Importin alpha mRNAs have distinct expression profiles during spermatogenesis. Dev. Dyn. 2006, 235, 253-262.s.
30. Kudo, N., Wolff, B., Sekimoto, T., Schreiner, E.P., Yoneda, Y., Yanagida, M., Horinouchi, S., Yoshida, M., Leptomycin B inhibition of signal-mediated nuclear export by direct binding to CRM1. Exp. Cell Res. 1998, 242, 540-547.
31. Jans, D.A., Xiao, C.Y., Lam, M.H., Nuclear targeting signal recognition: a key control point in nuclear transport? Bioessays. 2000, 22, 532-544.
32. Hubner, S., Xiao, C.Y., Jans, D.A., The protein kinase CK2 site (Ser111/112) enhances recognition of the simian virus 40 large Tantigen nuclear localization sequence by importin. J. Biol. Chem. 1997, 272, 17191-17195.
33. Alvisi, G., Jans, D.A., Guo, J., Pinna, L.A., Ripalti, A., A protein kinase CK2 site flanking the nuclear targeting signal enhances nuclear transport of human cytomegalovirus ppUL44. Traffic. 2005, 6, 1002-1013.
34. Zhao, X., Gan, L., Pan, H., Kan, D., Majeski, M., Adam, S.A., Unterman, T.G., Multiple elements regulate nuclear/cytoplasmic shuttling of FOXO1: characterization of phosphorylation-and 14-3-3-dependent and-independent mechanisms. Biochem. 2004, J. 378, 839-849.
35. M. Belting, S. Sandgren, A. Wittrup, Nuclear delivery of macromolecules: barriers and carriers, Adv. Drug Deliv. Rev. 2005, 57 (4), 505-527.
36. G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, L. Gianni, Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity, Pharmacol. Rev. 2004, 56 (2) 185-229.
37. K. Kiyomiya, S. Matsuo, M. Kurebe, Mechanism of specific nuclear transport of adriamycin: the mode of nuclear translocation of adriamycin-proteasome complex, Cancer Res. 2001, 61 (6), 2467-2471
38. M. Shi, K. Ho, A. Keating, M.S. Shoichet, Doxorubicin-conjugated immunonanoparticles for intracellular anticancer drug delivery, Adv. Funct. Mater. 2009, 19 (11), 1689-1696.
39. G. Sahay, D.Y. Alakhova, A.V. Kabanov, Endocytosis of nanomedicines, J. Control. Release. 2010, 145 (3), 182-195.
40. C. Cuvier, L. Roblottreupel, J.M. Millot, G. Lizard, S. Chevillard, M. Manfait, P. Couvreur, M.F. Poupon, Doxorubicin-loaded nanospheres bypass tumor-cell multidrug resistance, Biochem. Pharmacol. 1992, 44 (3), 509-517.
41. T.A. Elbayoumi, V.P. Torchilin, Enhanced cytotoxicity of monoclonal anticancer antibody 2 C5-modified doxorubicin-loaded PEGylated liposomes against various tumor cell lines, Eur. J. Pharm. Sci. 2007, 32 (3), 159-168.
42. D. Goren, A.T. Horowitz, D. Tzemach, M. Tarshish, S. Zalipsky, A. Gabizon, Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrugresistance efflux pump, Clin. Cancer Res. 2000, 6 (5), 1949-1957.
43. X.G. Li, D.J. Hirsh, D. Cabral-Lilly, A. Zirkel, S.M. Gruner, A.S. Janoff, W.R. Perkins, Doxorubicin physical state in solution and inside liposomes loaded via a pH gradient, BBA-Biomembranes. 1998, 1415 (1), 23-40.
44. S. Eksborg, Extraction of daunorubicin and doxorubicin and their hydroxyl metabolites-self-association in aqueous-solution, J. Pharm. Sci-US. 1978, 67 (6), 782-785.
45. M. Menozzi, L. Valentini, E. Vannini, F. Arcamone, Self-association of doxorubicin and related-compounds in aqueous-solution, J. Pharm. Sci-US. 1984, 73 (6), 766-770.
46. E.V. Batrakova, A.V. Kabanov, Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers, J. Control. Release. 2008, 130 (2), 98-106.
47. E.V. Batrakova, S. Li, V.Y. Alakhov, W.F. Elmquist, D.W. Miller, A.V. Kabanov, Sensitization of cells overexpressing multidrug-resistant proteins by Pluronic P85, Pharm. Res. 2003, 20 (10), 1581-1590.
48. E.V. Batrakova, S. Li, A.M. Brynskikh, A.K. Sharma, Y.L. Li, M. Boska, N. Gong, R.L. Mosley, V.Y. Alakhov, H.E. Gendelman, A.V. Kabanov, Effects of pluronic and doxorubicin on drug uptake, cellular metabolism, apoptosis and tumor inhibition in animal models of MDR cancers, J. Control. Release. 2010, 143 (3), 290-301.
49. A.V. Kabanov, E.V. Batrakova, V.Y. Alakhov, An essential relationship between ATP depletion and chemosensitizing activity of Pluronic(R) block copolymers, J. Control. Release. 2003, 91 (1-2), 75-83.
50. Y. Patil, T. Sadhukha, L.N. Ma, J. Panyam, Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance, J. Control. Release. 2009, 136 (1), 21-29.
51. S. Ganta, M. Amiji, Coadministration of paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells, Mol. Pharm. 2009, 6 (3), 928-939.
52. H.L. Wong, R. Bendayan, A.M. Rauth, X.Y. Wu, Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid Hybrid nanoparticle (PLN) for enhanced treatment of multidrugresistant breast cancer, J. Control. Release. 2006, 116 (3), 275-284.
53. P.Y. Li, P.S. Lai, W.C. Hung, W.J. Syu, Poly(L-lactide)-vitamin E TPGS nanoparticles enhanced the cytotoxicity of doxorubicin in drugresistant MCF-7 breast cancer cells, Biomacromolecules. 2010, 11 (10), 2576-2582.
54. M. Abbasi, A. Lavasanifar, L.G. Berthiaume, M. Weinfeld, H. Uludag, Cationic polymer-mediated small interfering RNA delivery for Pglycoprotein down regulation in tumor cells, Cancer. 2010, 116 (23), 5544-5554.
55. Y.C. Chen, S.R. Bathula, J. Li, L. Huang, Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer, J. Biol. Chem. 2010, 285 (29), 22639-22650.
56. Y.B. Patil, S.K. Swaminathan, T. Sadhukha, L.A. Ma, J. Panyam, The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance, Biomaterials. 2010, 31 (2), 358-365.
57. M. Susa, A.K. Iyer, K. Ryu, E. Choy, F.J. Hornicek, H. Mankin, L. Milane, M.M. Amiji, Z. Duan, Inhibition of ABCB1 (MDR1) expression by an siRNA nanoparticulate delivery system to overcome drug resistance in osteosarcoma, Plos One. 2010, 5 (5).
58. S. Yadav, L.E. van Vlerken, S.R. Little, M.M. Amiji, Evaluations of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells, Cancer Chemoth. Pharm. 2009, 63 (4), 711-722.
59. R.I. Pakunlu, Y. Wang, M. Saad, J.J. Khandare, V. Starovoytov, T. Minko, In vitro and in vivo intracellular liposomal delivery of antisense oligonucleotides and anticancer drug, J. Control. Release. 2006, 114 (2), 153-162.
60. N.M. Zaki, N. Tirelli, Gateways for the intracellular access of nanocarriers: a review of receptor-mediated endocytosis mechanisms and of strategies in receptor targeting, Expert Opin. Drug Deliv. 2010, 7 (8), 895-913.
61. D.J. Yoon, C.T. Liu, D.S. Quinlan, P.M. Nafisi, D.T. Kamei, Intracellular trafficking considerations in the development of natural ligand-drug molecular conjugates for cancer, Annu. Biomed. Eng. 2011, 39 (4), 1235-1251.
62. P.S. Low, S.A. Kularatne, Folate-targeted therapeutic and imaging agents for cancer, Curr. Opin. Chem. Biol. 2009, 13 (3), 256-262.
63. P.S. Xu, E.A. Van Kirk, Y.H. Zhan, W.J. Murdoch, M. Radosz, Y. Shen, Targeted charge-reversal nanoparticles for nuclear drug delivery, Angew. Chem. Int. Edit. 2007, 46 (26), 4999-5002.
64. Y. Shen, Z.X. Zhuo, M.H. Sui, J.B. Tang, P.S. Xu, E.A. Van Kirk, W.J. Murdoch, M.H. Fan, M. Radosz, Charge-reversal polyamidoamine dendrimer for cascade nuclear drug delivery, Nanomedicine-Uk. 2010, 5 (8), 1205-1217.
65. Z.X. Zhou, Y. Shen, J.B. Tang, M.H. Fan, E.A. Van Kirk, W.J. Murdoch, M. Radosz, Adv. Funct. Mater. 2009, 19 (22), 3580-3589.
66. S. Dhar, Z. Liu, J. Thomale, H.J. Dai, S.J. Lippard, Targeted singlewall carbon nanotube-mediated Pt(IV) prodrug delivery using folate as a homing device, J. Am. Chem. Soc. 2008, 130 (34), 11467-11476.
67. V. Anbharasi, N. Cao, S.S. Feng, Doxorubicin conjugated to D-alphatocopheryl polyethylene glycol succinate and folic acid as a prodrug for targeted chemotherapy, J. Biomed. Mater. Res. 2010, A 94 (3), 730-743.
68. J.J. Khandare, P. Chandna, Y. Wang, V.P. Pozharov, T. Minko, Novel polymeric prodrug with multivalent components for cancer therapy, J. Pharmacol. Exp. Ther. 2006, 317 (3), 929-937.
69. G. Ashwell, A.G. Morell, Role of surface carbohydrates in hepatic recognition and transport of circulating glycoproteins, Adv. Enzymol. Relat. Areas Mol. Biol. 1974, 41 99-128.
70. A.L. Schwartz, The hepatic asialoglycoprotein receptor, CRC Crit. Rev. Biochem. 1984, 16 (3), 207-233.
71. W. Wei, Z.G. Yue, J.B. Qu, H. Yue, Z.G. Su, G.H. Ma, Galactosylated nanocrystallites of insoluble anticancer drug for liver-targeting therapy: an in vitro evaluation, Nanomedicine-Uk.2010, 5 (4), 589-596.
72. N. Kolishetti, S. Dhar, P.M. Valencia, L.Q. Lin, R. Karnik, S.J. Lippard, R. Langer, O.C. Farokhzad, Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy, Proc. Natl. Acad. Sci. USA. 2010, 107 (42), 17939-17944.
73. X.B. Xiong, A. Mahmud, H. Uludag, A. Lavasanifar, Multifunctional polymeric micelles for enhanced intracellular delivery of doxorubicin to metastatic cancer cells, Pharm. Res. 2008, 25 (11), 2555-2566.
74. T.A. Elbayoumi, V.P. Torchilin, Enhanced cytotoxicity of monoclonal anticancer antibody 2 C5-modified doxorubicin-loaded PEGylated liposomes against various tumor cell lines, Eur. J. Pharm. Sci. 2007, 32 (3), 159-168.
75. D.J. Yoon, D.S.H. Chu, C.W. Ng, E.A. Pham, A.B. Mason, D.M. Hudson, V.C. Smith, R. T.A. MacGillivray, D.T. Kamei, Genetically engineering transferrin to improve its in vitro ability to deliver cytotoxins, J. Control. Release. 2009, 133 (3), 178-184.
76. Meihua Sui, Wenwen Liu, Youqing Shen, Nuclear drug delivery for cancer chemotherapy, Journal of Controlled Release. 2011, 155, 227-236